The NCCTG Gastrointestinal (GI) Cancer Program brings together specialists from all oncology disciplines with the following goals: 1. To improve cure rates when possible or extend survival/improve patient quality of life. a) Initiation/leadership of GI Intergroup/NCCTG phase III clinical trials. b) Participation in GI Intergroup trials led by other oncology groups. c) Rapid initiation/completion of Pilot Studies and Phase II trials, based on the most promising GI cancer treatment strategies developed in the Mayo Clinic Phase I program or elsewhere in collaboration with the NCCTG Novel Therapeutics Committee. This strategy manifests itself in the performance of targeted research studies across the eight primary GI tract sites. d) Integration of multiple modalities (surgery, radiation, and medical oncology) and participation of the appropriate modality committees in trial design and conduct. 2. To devise therapies that an be administered in proximity to the patient's home, with referral to specialized centers when approprite. a) By forging a research-driven partnership between the research and community bases. b) By conducting education symposia based in and around NCCTG meetings. 3) To further the understanding of tumor biology and host response through the investigation of prognostic determinants, factors influencing disease progression, and individual responses to chemotherapy (i.e. translational research). a) Interaction with Mayo Clinic researchers with expertise in correlative science. b) Collaboration with laboratory-based investigators elsewhere. 4. To utilize the extensive NCCTG database in completed studies to answer questions arising in clinical practice, from analyses of prospective trials, or from the literature. 5. To monitor and improve patient quality of life (QOL) and the tools to assess QOL. 6. To advance the field of clinical trials research by design of new trial paradigms and systems for optimal data collection in response to issues arising from our studies. 7. To entice involvement from diverse members of the multi-disciplinary oncology team in collaborations dedicated to extending the horizons of cancer care. This application will focus on the past, present, and projected future of the NCCTG GI Program based upon our accomplishments during the last grant period. We will delineate specific programmatic approaches that define the NCCTG GI Program based on the philosophical principles noted above. We will concentrate on our accomplishments in the prior grant period (present), and project the themes and outline the new initiatives that we hope will define our program in the next grant period (future).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA025224-22
Application #
6482030
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1982-01-01
Project End
2005-12-31
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Reinholz, Monica M; Chen, Beiyun; Dueck, Amylou C et al. (2017) IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res 23:4203-4211
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662

Showing the most recent 10 out of 718 publications